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 Abstract We previously reported that glucocorticoid receptor β (GRβ) regulates 
injury-mediated astrocyte activation and contributes to glioma pathogenesis via modulation of 
β-catenin/ T-cell factor/Lymphoid enhancer factor (TCF/LEF) transcriptional activity. The aim 
of this study was to characterize the mechanism behind cross-talk between GRβ and 
β-catenin/TCF in the progression of glioma. Here, we reported that GRβ knock-down reduced 
U118 and Shg44 glioma cell proliferation in vitro and in vivo. Mechanistically, we found that 
GRβ knock-down decreased TCF/LEF transcriptional activity without affecting 
β-catenin/TCF complex. Both GRα and GRβ directly interact with TCF-4, while only GRβ is 
required for sustaining TCF/LEF activity under hormone-free condition. GRβ bound to the 
N-terminus domain of TCF-4 its influence on Wnt signaling required both ligand binding and 
DNA-binding domains (LBD and DBD, respectively). GRβ and TCF-4 interaction is enough 
to maintain the TCF/LEF activity at a high level in the absence of β-catenin stabilization. 
Taken together, these results suggest a novel cross-talk between GRβ and TCF-4 which 
regulates Wnt signaling and the proliferation in gliomas.   
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Introduction 
Aberrant activation of the canonical Wnt signaling pathway has been linked to the formation 
and progression of multiple types of cancers [1]. β-catenin and TCF-4 are the core 
components of the canonical Wnt pathway. Upon activation, β-catenin accumulates in the 
nucleus, where it interacts with TCF-4 and LEF-1, to form a β-catenin/TCF-4/LEF-1 complex 
that allows regulation of Wnt target genes known to be important for human tumorigenesis 
such as c-Myc [2] and Cyclin D1 [3]. Disruption of β-catenin-TCF-4/LEF-1 complex may be 
an ideal potential therapeutic target for controlling tumor formation and progression [4]. 
Meanwhile, other co-factors such as ATF2 [5] and IGFR1 [6] can interact with TCF/LEF and 
activate its transcriptional activity in the absence of β-catenin stabilization. Therefore, 
identifying co-factors and elucidating their interaction mechanism improves the 
understanding of TCF/LEF involvement in cancer biology.  
The glucocorticoid receptor (GR) functions as a hormone-activated transcription factor 
that regulates the expression of numerous glucocorticoid responsive genes and controls 
multiple cellular events. The human GR gene generates two C-terminal receptor isoforms, 
GRα and GRβ, by alternative splicing of exons 9α and β respectively. GRα is transported into 
nucleus in the presence of hormone and binds to glucocorticoid response elements (GREs) in 
regulatory regions of glucocorticoid-responsive genes, attracts co-activators and influences 
transcription. GRα also interacts with other transcription factors to facilitate trans-repression 
or trans-activation of genes [4]. GRβ shares the same N-terminal (NTD) and DNA-binding 
domains (DBD) with GRα but possesses a unique “ligand-binding” domain (LBD). A 
different C-terminal region with 15 non-homologous amino acids is located in the LBD. GRβ 
is primarily located in the nucleus where it negatively regulates GRα activity. Recently, GRβ 
was shown to exhibit intrinsic transcriptional activity and function as a transcriptional factor 
via a GRα-independent manner [5,6].  
Cross-talk between GR and β-catenin-TCF/LEF has been reported in several studies, and 
GRα acts as a trans-repressor on β-catenin-TCF signaling [7-9]. While, GRα is predominately 
located in cytoplasm under hormone-free condition [10], suggesting GRα exerts its 
trans-repression on β-catenin-TCF signaling is hormone dependent. Our recent study 
demonstrated that GRβ enhances β-catenin-TCF signaling through negative regulation of 
GRα function in the presence of hormone [9]. Mechanically, the interplay between GRβ and 
β-catenin was demonstrated to be a necessary component of astrocyte reactivity through 
sustained Wnt/β-catenin/TCF signaling in its dominant-negative effect on GRα mediated 
trans-repression by a GSK-3β-independent manner. Several reports have shown that aberrant 
activation of Wnt/β-catenin/TCF signaling is an important contributing factor in glioma 
development (Ref) [11-13]. Our previous finding that GRβ is predominately distributed in the 
nucleus and contributes to glioma pathogenesis raises the consideration that the cross-talk 
between GRβ and β-catenin/TCF signaling involves in the progression of glioma [9].     
To investigate such a role for GRβ, we established stable GRβ knock-down glioma cell 
line from U118MG and Shg44 glioma cells. We demonstrated that GRβ regulates glioma cell 
proliferation by enhancing TCF/LEF without modifying the expression or nuclear localization 
of β-catenin. GRβ directly interacted with TCF-4 independently of β-catenin and regulated 
TCF/LEF activity in a GRα-independently manner, indicating that GRβ is a co-activator for 
TCF/LEF and their communication plays important roles in the Wnt signaling pathway.  
 
Materials and Methods 
Cell Culture  
Human glioma cell line, U118MG and Shg44, the monkey kidney cell line, COS-1, human 
embryonic kidney cell line, HEK293, and human breast carcinoma cell line, MDA-MB-453, 
were obtained from the Cell Bank of Type Culture Collection of the Chinese Academy of 
Sciences (Shanghai, China) and cultured in DMEM with 10% fetal bovine serum (FBS; 
Invitrogen, Carlsbad, CA). The stable GRβ knockdown glioma cell cultures were derived 
from U118 and Shg44 cells transfected with GRβ lentiviral shRNA or a scramble vector. The 
lentiviral GRβ shRNA and scramble vector were purchased from Genechem. The target 
sequence of shRNA for GRβ was described in a previous study [9]. Cell lines > 90% purity 
were used in subsequent experiments. The stable GRβ knockdown cells were labeled 
siGRβ-U118 and siGRβ-Shg44. The stable scramble control cells were labeled scGRβ-U118 
and scGRβ-Shg44.  
 
Subcutaneous implantation assay  
To establish subcutaneous xenograft models, cells (2 X 106 in 100 μl physiological saline) 
were subcutaneously injected into nude mice (BALB/c nu/nu mice, National Rodent 
Laboratory Animal Resources, Shanghai, China ). After 28 days, the mice were sacrificed and 
solid tumors were carefully harvested and tumor weight was measured immediately. All 
mouse experiments were approved by the animal care committee at Nanjing Medical 
University and were carried out in accordance with government and institutional guidelines 
and regulations.  
 
RNA Interference and Transfection 
The siRNA sequences targeting human TCF-4 (GeneBank NM_001243236.1) and human GR 
(NR3C1, GeneBank NM_001018076.1) were 
5’-GGGACAGACAGUAUAAUGGCAAAUAGAtt-3’ and 
5'-GGAGCUACUGUGAAGGUUUtt-3', respectively [14,15]. Their scrambled sequences 
served as negative controls (NC). These siRNA sequences were synthesized by Genepharma 
(Shanghai, China). For transfection, cells were cultured in DMEM supplemented with 10% 
FBS. 12 h after seeding, cells were transfected with the different siRNA duplexes using 
X-tremeGene siRNA transfection Reagent (Roche, Mannheim, Germany) at a final 
concentration of 100 nM. For Western blot analysis, cell proteins were prepared at 72 h after 
transfection.  
 
Vector Construction 
The hGRα and hGRβ expression vectors, GFP-hGRα and pDsRed-hGRβ used in the present 
study were derived from methods described in our previous study [9]. The mutants of hGRβ 
were PCR-amplified from the constructed wide-type (wt) GRβ plasmid and cloned into a 
pDsRed1-N1 vector. The TCF-4 plasmid (Myc-TCF-4) [14] was obtained from the Addgene 
plasmid depository (Addgene plasmids 16512). A dominant negative mutant of TCF-4 
(Myc-dnTCF-4, 1-80 amino deletion mutant) was amplified from the Myc-TCF-4 plasmid. 
 
Cell Growth Assay 
The cell growth assay procedure utilized was based on MTS as described previously [16]. 
Briefly, for assaying the effect of gene silencing on cell growth, cells were cultured in 96-well 
culture plates (1000 cells/well) and transfected with TCF-4 siRNA (100 nM) or GR siRNA  
targeting to the common sequence of GRα and GRβ (100 nM). A scrambled sequence was 
used as a negative control. Cell growth was determined by quantifying viable cell number 
using a One Solution Cell Proliferation Assay Kit (Promega, Madison, WI) at indicated time 
periods (0 h, 24 h, 48 h and 72 h) after transfection. The living cell number was assessed by 
measuring absorbance of OD570. Each experiment was repeated six times and measurements 
were made in triplicate. 
 
EdU Cell Proliferation Assay 
A novel thymidine analog, 5-ethynyl-2′-deoxyuridine (EdU) was used to mark DNA synthesis 
in proliferating cells [17]. Briefly, the U118 and U87 stable cells were cultured on poly-lysine 
(Sigma, St. Louis, MO) coated coverslips for 24 h followed by an incubation of EdU 
(Invitrogen) for 12 h. The cells were fixed with 4% paraformaldehyde (PFA) and the staining 
procedure was followed according to the manufacturer’s instructions for the Click-iT® EdU 
Cell Proliferation Assays kit (Invitrogen). After staining, the coverslips were mounted with 
Gelmout containing Hoechst 33342 (Sigma) for nuclear labeling.  
 
Colony Formation Assay 
Colony formation assay was used to measure the ability of a single cell to grow into a colony 
[16]. In brief, before harvesting from donor cultures, 4 randomly selected stable glioma cell 
lines in individual group were serum starved for 24 h. After trypsinized to produce a 
single-cell suspension, the cells were diluted into 50 cells per well and seed on 6-well plate. 
The cultures were allowed to grow for 14 days. The number of colonies > 50 cells was 
counted after Coomassie blue staining.  
 
Western Blot  
For Western blot analysis, cells were harvested and lysed in RIPA lysis buffer (Cell Signal 
Technology, Beverly, MA). To investigate subcellular distribution of proteins, nuclear and 
cytoplasmic fractions were enriched using Nuclear and Cytoplasmic Protein Extraction Kit 
(CoWin Bioscience, China).Western blot analysis was performed as previously reported [16]. 
Antibodies used included rabbit anti-Cyclin D1 (1:1000, Abcam, Cambridge, UK), rabbit 
anti-TCF-4 (1:1000, Abcam), rabbit anti-β-catenin (1:1000, Cell Signal Technology), mouse 
anti-β-actin (1:2000, Abmart, China), and mouse anti-Histone H3 (1:1000, Abmart).  
 
RT-PCR 
RT-PCR was used to confirm the TCF-4 siRNA transfection by measuring the TCF-4 mRNA 
level in U118 and Shg44 cell lines 48 h after the transfection. Total RNA isolation, reverse 
transcription and amplified were performed as described previously [18]. The primers for 
PCR were as follows: TCF-4 (fwd, 5'-CGAGGGTGATGAGAACCTGC-3'; rev, 
5'-CCCATGTGATTCGATGCGT-3'); β-actin (fwd, 5'-CTCCATCCTGGCCTCGCTGT-3'; 
rev, 5'-GCTGTCACCTTCACCGTTCC-3'). β-actin served as a loading control.  
 Immunoprecipitation 
Immunoprecipitation (IP) was performed as previously described [9]. In brief, cell lysates 
were precipitated using Protein A/G beads (Abmart) with varying antibodies. Precipitated 
products were assessed by immunoblot (IB) analysis. Antibodies used in IP and IB are 
described in the figure legends.  
 
Immunofluorescence Staining 
Immunofluorescence (IF) procedures were performed as previously reported [15]. Briefly, 
cells were fixed in 4% PFA and labeled with primary antibodies overnight. The primary 
antibodies used in double IF included mouse anti-TCF-4 (1:100, Millipore, Bedford, MA) and 
rabbit anti-GRβ (1:200, Genetex) or rabbit anti-GRα (1:100, Abcam). Cell nuclei were 
counterstained with Hoechst 33342. The primary antibodies used in triple IF included 
conjugated goat anti-β-catenin (1:50, Santa Cruz, CA), rabbit anti-GRβ and mouse 
anti-TCF-4. The following day, primary antibody was washed from the coverslips followed 
incubation with DyLight 405, 488 and 594-conjugated secondary antibodies. Coverslips were 
then washed and the staining was visualized using an Olympus IX71 microscope. 
 
TCF/LEF Transcriptional Reporter Assay 
TCF transcriptional reporter activity assessment was performed as previously described [9]. 
Briefly, cells were transiently transfected with a Tcf-4-responsive luciferase plasmid, 
pGL3-OT (Addgene plasmids 16558) or a mutant Tcf-4-responsive luciferase plasmid, 
pGL3-OF (Addgene plasmids 16559) for 48 h [19]. The pRL vector was also transfected as 
an internal control reporter. Luciferase activity was measured using the Dual-Glo Luciferase 
Assay System kit.  
 
Chromatin Immunoprecipitation (ChIP) Assay 
The cells were cross-linked with 1% formaldehyde and lysed. ChIP assays were performed 
according to the manufacturer's protocol (Beyotime, China) with slight modifications. 
Chromatin solutions were sonicated and incubated with anti-TCF-4 overnight at 4°C. Normal 
rabbit serum was used as a negative control. An anti-RNA polymerase II antibody (Pierce，
Roclford, IL) was used as a positive control. GAPDH primers (sense, 
5'-tactagcggttttacgggcg-3', anti-sense, 5'-tcg aacaggaggagcagagagcga-3') were supplied by the 
ChIP assay kit. DNA–protein cross-links were reversed and chromatin DNA was purified and 
subjected to PCR analysis. The primers (sense, 5’-catgctaaattagttcttgca-3’; antisense, 
5’-ctggggagaccacgagaa-3’) for Cyclin D1 proximal promoter (National Center for 
Biotechnology Information, Genbank X59798) were used to amplify the precipitated DNA 
[20]. After amplification, PCR products were resolved on a 1.5% agarose gel and visualized 
by ethidium bromide staining. For input control, the non-IP DNA-protein complex was 
performed using the same primers.  
 
Statistical Analysis 
SPSS 12.0 was applied to carry out statistical analyses. Data were presented as mean + SEM, 
and statistical analysis was carried out by analysis of variance, followed by Student’s t test 
with a significance of p<0.05. 
 
Results 
GRβ Knock-down Impairs the Proliferation of U118 and Shg44 Glioma Cells  
Our previous study reported that GRβ regulates the reactive response of astrocytes after injury 
by modulating β-catenin/TCF signaling and knock-down of GRβ impaired biological 
characteristics of glioma cells [9]. To further investigate the significance of GRβ in glioma, in 
the present study we established stable U118 and Shg44 glioma cells derived from GRβ 
knock-down (siGRβ-U118 and siGRβ-Shg44) and scramble shRNA transfected (scGRβ-U118 
and scGRβ-Shg44) U118 and Shg44 cells using lentivial shRNA vectors based on previously 
reported sequence [9,21]. No changes in cell viability and apoptosis were observed in these 
cells (data not shown). Similar to the previous study, GRβ knock-down resulted in a cell 
growth inhibition in these glioma cells (Fig. 1a,b). This effect was further demonstrated by an 
EdU incorporation experiment (Fig. 1c,d). GRβ knock-down also resulted in a suppression of 
colony formation (Fig. 1e,f). Furthermore, when transplanted into nude mice, siGRβ-U118 
and siGRβ-Shg44 formed smaller tumors than scGRβ-U118 and scGRβ-Shg44 cells (Fig. 
1g).These findings support our previous results suggesting that GRβ plays a significant role in 
the proliferation of glioma cells. 
 
GRβ Knock-down Reduces Transcriptional Activity of β-catenin/TCF in Glioma Cells 
To determine whether GRβ regulates cell growth of glioma cells through modulation of 
β-catenin/TCF signaling, the stable cells were transfected with a TCF/LEF reporter plasmid, 
pGL3-OT, to monitor β-catenin/TCF mediated transcriptional activity [19]. The activity of 
β-catenin/TCF was measured by the relative luciferase activity of pGL3-OT. As shown in Fig. 
2a,b, GRβ knock-down resulted in a significant reduction of basal β-catenin/TCF activity in 
siGRβ-U118 cells and siGRβ-Shg44 cells. pGL3-OF, containing a mutant TCF-4 binding site, 
served as a negative control and did not significantly change in these cells (data not shown). 
Accordingly, the expression of β-catenin/TCF targeting gene, Cyclin D1 was decreased in 
siGRβ-U118 (Fig. 2c) and siGRβ-Shg44 cells (Fig. 2d). Further experiment in ChIP assay in 
U118 stable cells revealed a significantly reduced binding of TCF-4 to its target gene 
promoter, Cyclin D1 (Fig. 2e). These results suggested the possibility that GRβ regulates 
glioma cell proliferation by modulating β-catenin/TCF activity.   
 
GRβ Regulates Glioma Cell Proliferation Independently of β-catenin-TCF-4 Complex  
The nuclear β-catenin-TCF complex plays a pivotal role in β-catenin/TCF signaling and 
activation of Wnt target genes [22]. We next examined whether the decreased β-catenin/TCF 
transcriptional activity was caused by the reduction of TCF-4 and β-catenin expression or 
their interaction after GRβ knock-down. As shown in Fig. 2c and d, no detectable change in 
TCF-4 and β-catenin was observed in total protein of stable U118 and Shg44 cells after GRβ 
knock-down. In Wnt signaling pathway, nuclear β-catenin forms a complex with TCF/LEF 
and regulates the expression of Wnt target genes; however, immunoprecipitation (IP) 
experiment revealed that GRβ knock-down did not induce detectable change in 
β-catenin-TCF-4 interaction (Fig. 3a). Aberrant or sustained Wnt signaling has been linked to 
human cancers and the nuclear β-catenin-TCF complex acts as a critical aspect of the 
responsiveness of a cell to a specific Wnt signaling via a β-catenin responsive transcription 
(CRT) mechanism [22]. Triple immunostaining with β-catenin, TCF-4 and GRβ showed that 
only a small portion of β-catenin co-localized with TCF-4 in nuclei of U118 cells and Shg44 
cells (Fig. 3b). As shown in the IP experiment (Fig. 3c), only a weak interaction of β-catenin 
and TCF-4 was observed in these two cell lines. In this experiment, HCT116 cells, a cell line 
with constitutively elevated levels of CRT acted as a positive reference [22]. It suggested that 
the CRT mediated transcription may be not a vital contributor for glioma cells growth. To test 
this idea, iCRT3, a Wnt signaling inhibitor which specifically inhibits CRT activity by 
disrupting β-catenin-TCF interaction [22] was used in the cell growth assay (Fig. 3d-f). As a 
positive control, the cell growth of HCT116 was significantly inhibited by the iCRT3 
treatment (Fig. 3d). While, such growth inhibition was not observed in U118 and Shg44 cells 
(Fig. 3e,f). Meanwhile, a TCF-4 specific siRNA mediated knock-down resulted in a 
significant growth inhibition both in U118 cells and Shg44 cells (Fig. 3g,h), indicating TCF-4 
mediated transcriptional activity is an important regulator for U118 cell growth. Therefore, 
these observations demonstrated that TCF-4 has β-catenin-independent effects mediated 
regulation of cell growth of glioma cells and the regulation of GRβ on glioma cell 
proliferation is β-catenin-TCF complex independently.  
 
GRβ Interacts with TCF-4 Directly by Binding with Its N- terminus 
Previous observations have provided evidences that TCF proteins have effects independent of 
β-catenin mediated activation of target genes [23]. As GRβ modulated TCF/LEF 
transcriptional activity and regulated cell growth in a CRT-independent manner in U118 and 
Shg44 glioma cells, we speculated a new mechanism for TCF/LEF transcriptional activity 
mediated by GRβ distinct from that associated with canonical Wnt signaling. We supposed 
that GRβ might be a transcription co-factor of TCF-4 and sustains activation of Wnt signaling. 
To test this hypothesis, we first investigated whether GRβ interacts with TCF-4. The 
immunostaining shown in Fig. 4a, as well as the triple immunostaining in Fig. 3b show that 
GRβ was mainly distributed in the nucleus and co-localized with TCF-4, while GRα was 
predominately expressed in cytoplasm. The IP results showed that both GRβ and GRα can 
interact with TCF-4 in U118 glioma cells. It also indicated that the amount of GRα interacting 
with TCF-4 was significantly less than that shown for GRβ (Fig. 4b). This outcome perhaps 
resulted from the predominately cytoplasmic distribution of GRα, indicating no obvious effect 
of GRα on Wnt signaling in U118 cells was associated with its low activity under 
hormone-free conditions. Since our previous study demonstrated an interaction between GR 
and β-catenin, we performed an IP experiment to examine whether the binding of TCF-4 and 
GRβ or GRα was β-catenin-independent. The β-catenin negative MDA-MB-453 cells  [24] 
were co-transfected with plasmids of Myc-TCF-4 and pk7-GRα-GFP or pDsRed1-GRβ (ratio, 
2:1) and cell proteins were immunoprecipitated with mouse anti-Myc antibody followed by 
immunoblot (IB) with rabbit anti-Myc and GFP or RFP antibodies. As shown in Fig. 4c, the 
two recombinant GR isoforms could interact with recombinant TCF-4 in a 
β-catenin-independent manner. The first 80 amino of TCF-4 has been reported to be important 
for TCF-4 binding its co-factors [25]. To investigate whether this domain is involved in the 
interaction of TCF-4 and GRα or GRβ, we expressed pDsRed1-GR727 (mutant with the same 
amino acid 1–727 region of GRα and GRβ) and N-terminal (1-80) deletion mutant of TCF-4 
(dominate negative mutant of TCF-4, Myc-dnTCF4) in the GR-free COS-1 cell line. IP 
experiment showed that the deletion of N-terminal domain blocked the interaction of TCF-4 
and GR (Fig. 4d). These experiments suggested that the N-terminal domain of TCF-4 
contributes to its interaction with GRα and GRβ.  
 
GRβ, not GRα Affects the Transcriptional Activity of TCF/LEF in Glioma Cells 
Activated GRα stimulated by dexamethasone (Dex) can inhibit growth in glioma cells [26,27]. 
In addition, this inhibition was further enhanced in GRβ knock-down glioma cells 
(Supplementary Fig. 1a). GRα acts as a trans-repressor of Wnt/β-catenin signaling, while 
GRβ has a negative effect on the function of GRα [4,9]. As expected, GRβ knocking-down 
promoted the inhibition of GRα on TCF/LEF activity under Dex stimulation (Supplementary 
Fig. 1b). The result is consistent with our previous finding that GRβ exerts negative effect on 
GRα mediated trans-repression on Wnt signaling. To investigate whether the reduction of 
TCF/LEF activity after GRβ knock-down was associated with the repressive effect of GRα 
under hormone free condition, TCF/LEF transcriptional activity was examined in 
siGRβ-U118 cells following a GR siRNA transfection which targeted a common sequence of 
GRα and GRβ. No detectable change of TCF/LEF activity or Cyclin D1 expression was 
observed in these cells after GR knock-down (Fig. 5a,b). GR knock-down by GR siRNA 
transfection had no effect on siGRβ-U118 cell proliferation (Fig. 5c). It suggested that GRα is 
not a key repressive factor on Wnt/β-catenin signaling in siGRβ-U118 cells under 
hormone-free conditions. Next, we investigated whether GRβ transfection could rescue the 
TCF/LEF transcriptional activity in siGRβ-U118 cells. A ChIP assay using anti-TCF-4 
antibody was performed to confirm this. The siGRβ-U118 cells were transfected with 
pDsRed1-GRβ or pDsRed1 plasmid. As shown in the ChIP assay (Fig. 5d), the increase in 
GRβ enhanced the binding of TCF-4 to the Cyclin D1 promoter in GRβ knock-down cells. It 
also resulted in an increase of Cyclin D1 expression as shown in the Western blot assay (Fig. 
5e). These results suggested that GRβ modulates TCF activity in U118 cells via a 
GRα-independent mechanism.  
 
The Effects of GRβ on Wnt Signaling is Dependent on the DBD and LBD Domain 
We attempted to reciprocally determine which domain of GRβ is critical for its interaction 
with TCF-4. For this purpose, an IP experiment was performed in HEK293 cells 
co-transfected with different deletions of GRβ and Myc-TCF-4 (Fig. 6a,b). The results 
showed that the GRβ 1-488^556-742 mutant cannot bind to TCF-4 indicating the DBD 
(418-488) is essential for the binding of GRβ to TCF-4 (Fig. 6b). Furthermore, to determine 
whether GRβ induction of Wnt-mediated transcription is dependent upon the DBD domain, 
we co-expressed GRβ mutants with Myc-TCF-4 in COS-1 cells. Results from a luciferase 
experiment with pGL3-OT/OF reporters showed that wide-type GRβ and the GRβ 418-742 
mutant significantly increased Wnt1-mediated luciferase activity (Fig. 6c). This indicated that 
the NTD (1-418) is not critical for TCF-4 binding and transactivation of TCF/LEF. These 
results also demonstrated that besides the DBD, the whole LBD (488-742) including the 
activation functions 2 (AF2) domain is essential for transactivation of GRβ. Mifepristone 
(RU486) acts as an antagonist of GRβ by binding the LBD of GRβ [4,5]. Here we showed 
that although RU486 treatment resulted in a growth inhibition in U118 and Shg44 cells 
(Supplementary Fig. 2a,b), it did not affect TCF/LEF activity (Supplementary Fig. 3a) or the 
binding capacity of GRβ to TCF-4 (Supplementary Fig. 3b). It is possible that RU486 may 
inhibit GRβ intrinsic transcriptional activity via a TCF/LEF independent manner and the 
ligand-binding function of LBD does not affect the interaction of GRβ and TCF-4.  
 Discussion 
Wnt/β-catenin/TCF signaling and β-catenin/TCF/LEF complex are important contributors to 
the development of multiple cancers including glioma [28,13,12]. The findings presented here 
revealed for the first time that GRβ serves as a co-activator for Wnt signaling potentiating 
glioma progression by interacting to TCF-4. By directly binding to TCF-4, GRβ sustains 
TCF/LEF transcriptional activity independent of β-catenin. The glucocorticoid receptor (GR) 
binds to GREs in the promoters of glucocorticoid responsive genes activates their 
transcription, and regulates activity and suppression of other transcriptional factors. The role 
of GR isoforms have been widely investigated and GRα, in particular, mediates most of the 
known actions of GR [29]. In contrast, the functions of GRβ have been remained largely 
unknown. GRβ is known as a dominant negative regulator of GRα-mediated transcriptional 
activity; however, previous research has demonstrated that GRβ exerts positive and negative 
influence on the transcriptional activity of large subsets of genes, most of which are not 
responsive to glucocorticoids [4]. Here we expanded the understanding of GRβ function and 
further uncovered a novel mechanism in the regulation of other genes’ transcriptional activity 
(see model in Figure 7). .  
Under glucocorticoid stimulation, ligand-bound GRα undergoes nuclear translocation 
and negatively regulates Wnt signaling through indirect and direct binding to β-catenin [7,30]. 
As revealed in this study, interaction between GRα and TCF-4 suggests that GRα may 
regulate the transcriptional activity of TCF-4 via a β-catenin-independent process. In glioma 
cells with low level of nuclear β-catenin, the trans-repression of GRα on TCF/LEF activity 
was further enhanced by GRβ knock-down under glucocorticoid stimulation. This introduces 
the possibility that the negative effect of GRβ on GRα in Wnt signaling is mediated through 
competitive binding of GRβ and GRα to TCF-4. This interaction occurred in nuclei and 
whereas GRα is predominately localized in cytoplasm; therefore, the negative function of 
GRα on TCF-4 is likely hormone-dependent. As a result, no increase of TCF/LEF activity 
was observed following GR knock-down under hormone-free condition. We propose that 
GRβ is an active factor in Wnt signaling in glioma cells, rather than a protein simply affiliated 
with GRα.  
The nuclear β-catenin-TCF complex plays a central role in the transcription of Wnt 
target genes [13]. Our observation that GRβ interacted with β-catenin and TCF-4 implies that 
GRβ can affect β-catenin binding to TCF-4. Meanwhile, no changes in β-catenin and 
β-catenin-TCF-4 complex expression were observed after GRβ knock-down. This suggests that 
GRβ can modulate TCF/LEF activity without affecting the β-catenin-TCF complex. High 
Wnt/β-catenin activity is believed to be associated with increased malignancy and adverse 
outcome of gliomas [31,12,32,33]. TCF-4 and the β-catenin-TCF-4 complex promote glioma 
cell growth and stemness upon Wnt signaling activation [31, 36]. While, under normal culture 
conditions, the minimal nuclear β-catenin distribution and β-catenin-TCF complex is not 
sufficient to direct growth in U118 and Shg44 cells. However, TCF-4 still emerged as a key 
factor which regulated growth in these cells. The newly identified function of GRβ, as well as 
previous findings [34], indicate TCF/LEF transcriptional activity is affected by multiple 
factors, and not just limited by β-catenin activity. Unlike p15Rs [32], the involvement of GRβ 
in Wnt signaling does not appear to occur through disrupting or enhancing the interaction of 
β-catenin and TCF-4. The present observation that the N terminus of TCF-4, which serves as 
the binding site for β-catenin [35], allowed for binding to GRβ implies that GRβ may 
competes with inhibitory factors like p15Rs [36] and GRG5/AES [37] for binding to TCF-4. 
Nevertheless, these results suggest that the GRβ/TCF-4 transaction complex is an additional 
target in Wnt signaling for inhibiting tumor development and progression. However, the 
present study cannot rule out the involvement of cross-talk between cytoplasmic β-catenin 
and GRα or β without GR ligand. Our unreported data showed that siRNA targeting β-catenin 
resulted in inhibited growth in glioma cells, without inducing a significant decrease of 
TCF/LEF activity. These findings suggested that the cell growth regulation of β-catenin is not 
occurs independently of TCF/LEF mediated transcription [38,39]. The interaction of β-catenin 
and GRα or GRβ reported in our previous study indicates that the interaction of cytoplasmic 
β-catenin and GRα or GRβ may also play roles in the regulation of cell proliferation via a 
presently unclear mechanism [9]. 
Our observation that the DBD is essential for GRβ binding to TCF-4 indicated that GRα 
and GRβ share the same TCF-4 binding domain. This also implies that competitive interaction 
exists between GRα and GRβ. In the absence of hormone, GRα is a cytoplasmic-dominant 
protein. To intensify the inhibitory activity of GRα on Wnt signaling, it is possible that GR 
interacts with TCF/LEF in a hormone-independent manner while repressing the activity of 
TCF/LEF as observed in the presence of hormone. Another feasible method to verify this is to 
introduce a recombinant nuclear-forcing DBD protein to block the GR binding site of TCF-4. 
Other than the DBD, the enhancement of TCF/LEF activity by GRβ required the entire LBD, 
suggesting the differing action in regulating Wnt signaling between GRα and GRβ may be 
due to divergence at the 728th amino acid residue of the GR isoforms. Two AF2 domains have 
been mapped to the LBD of human GRα. The AF2 domain (residues 526-556) possesses 
transactivation potential in the context of full-length GRα by recruiting co-regulators 
[40,30,41,42]. The C-terminal AF2 domain (residues 728-763 or 753-768) of GRα is 
responsible for hormone-dependent interaction with co-activators of the p160 family, e.g. 
SRC-1 [43,44]. The observation that the AF2 domain (residues 526-556) is essential for the 
modulation of GRβ on TCF/LEF suggests that different co-regulators recruited through this 
region lead to different action of GR isoforms. Our study demonstrated that the DBD-AF2 
domain (residues 418-556) is unable to take on the action of GRβ on Wnt signaling which 
indicates that GRβ action is a cooperative process involving these three components. As a 
result of the hormone-independent action of GRβ, the C-terminal domain (residues 728-742) 
may be a distinct functional domain that determines transaction or transrepression of GRβ; 
however, its exact function has not been clearly defined. In addition, the observation that 
RU486-binding LBD did not exert inhibition on of GRβ and TCF-4 interaction and TCF/LEF 
activity indicated that the ligand only affects the direct modulation of GRβ on gene 
transcriptional activity; it does not affect transcriptional modulation of GRβ on other 
transcription factor activities by incorporating into the transcriptional intermediate complex.  
In conclusion, the findings shown in the present study help redefine GRβ as a new 
nuclear positive-regulator of the Wnt signaling through TCF-4 interaction in glioma cells. 
This discovery extends our understanding of GR action to Wnt signaling, which reveals new 
questions and possibilities concerning the role and mechanistic activity of GR in cellular 
activities. Given the well-established roles of Wnt signaling in various cancers, we expect that 
our findings on the functional interaction of GRα and GRβ with TCF-4 will provide useful 
information for the development of effective therapies against glioma and related disease. 
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Figure legends 
Fig. 1 GRβ knock-down impaired the proliferation of U118 and Shg44 glioma cells in vitro 
and in vivo. a,b A cell growth assay showed growth inhibition in stable GRβ knock-down 
U118 glioma cells (siGRβ-U118) and Shg44 glioma cells (siGRβ-Shg44). **p<0.01, vs. 
Scramble control cells (scGRβ-U118 or scGRβ-Shg44), n=6. Insets showed the Western 
blotting results depicting the effect of GRβ knockdown. c,d EdU incorporation experiment 
demonstrated inhibited proliferation in siGRβ-U118 cells and siGRβ-Shg44. The upper panels 
illustrated the double staining of EdU (Red) and nuclei (Hoechst, blue). Lower panels showed 
the quantification of EdU positive cells. Data were expressed as the percentage of EdU to 
Hoechst labeling. *p<0.05, n=6. Scale bar, 50 μm. e,f GRβ knock-down resulted in a 
suppression of colony formation. Cell colonies were counted and plotted. *p <0.05, n=4. g 
GRβ knock-down suppressed the tumor formation in a human glioma xenograft mouse model. 
Representative images (top) and weight (bottom) of tumors obtained from nude mice injected 
subcutaneously with U118 or Shg44 stable cells. **p< 0.01, n=6. 
 
 
Fig. 2 GRβ knock-down decreased TCF/LEF transcriptional activity in glioma cells. a,b 
Luciferase reporter assays showed TCF/LEF transcriptional activity in U118 (a) and Shg44 (b) 
cells after GRβ knock-down. Luciferase assays were performed in U118 or Shg44 stable cells 
transfected with an OT/OF-Luc Flash reporter and pRL-TK (as an internal control). Relative 
luciferase activities were normalized with the internal control. **p< 0.01, n = 6. c,d Western 
blot analysis of Cyclin D1, TCF-4 and β-catenin in U118 and Shg44 stable cells. β-actin 
served as a loading control. The quantification of relative Cyclin D1 expression was shown in 
the right panel. **p< 0.01, n = 3. e ChIP assay showed decreased binding of TCF-4 to the 
Cyclin D1 promoter in GRβ stable knock-down U118 cells. The ChIP DNA samples obtained 
using anti-TCF-4 antibody, anti-RNA polymerase II antibody (Anti-Poly II) or a normal IgG 
were subjected to PCR to amplify the Cyclin D1 or GAPDH fragment using specific promoter 
primers. For input, 1% of the Non-IP samples were used. The right panel shows the 
quantification of the relative DNA binding determined using the ratio of anti-TCF-4/Input. 
*p< 0.05, n = 3. 
 
Fig. 3 Cell growth regulation of GRβ in U118 cell is β-catenin-TCF complex independently. a 
Immunoprecipitation (IP) analysis showed no change of TCF-4 and β-catenin interaction in 
U118 and Shg44 cells after GRβ knock-down. Cell proteins were immunoprecipitated with 
mouse anti-TCF-4 antibody and analyzed by an immunoblot (IB) with rabbit anti-TCF-4 and 
β-catenin antibodies. b Triple immunostaining of β-catenin (Red), GRβ (Green) and TCF-4 
(blue) of normal U118 and Shg44 glioma cells. c IP analysis of TCF-4 and β-catenin in 
normal HCT116, U118 and Shg44 cells. d-f Cell growth assay of normal HCT116 (d), U118 
cells (e) and Shg44 cells (f) treated with iCRT3 (25 μM) or DMSO. **p< 0.01, n = 6. g,h Cell 
growth assay showed a growth inhibition in normal U118 cells (g) and Shg44 cells (h) after a 
TCF-4 siRNA transfection. **p< 0.01, n = 6. Insets showed the RT-PCR results depicting the 
effect of TCF-4 siRNA transfection.  
 
Fig. 4 GRβ interacted with TCF-4 directly by binding to its N-terminus. a Double 
immunostaining of TCF-4 (green) and GRβ or GRα (red) in normal U118 cells. GRβ 
exhibited a predominantly nuclear distribution and co-localized with TCF-4. GRα was mainly 
distributed in the cytoplasm and showed minimal co-localization with TCF-4. Hoechst served 
as a nuclear staining. Bars, 20 µm. b TCF-4 interacted with GRα and GRβ in U118 cells. Cell 
proteins were immunoprecipitated with mouse anti-TCF-4 antibody and analyzed by IB with 
rabbit anti-TCF-4 and GRα or GRβ antibodies. The lower panel shows the quantification of 
relative binding of GRα or GRβ to TCF-4. *p<0.05, n=3. c GRα and GRβ interacted with 
TCF-4 in a β-catenin independent manner. MDA-MB-453 cells were transfected with 
Myc-TCF-4 and pk7-GRα-GFP (left panel) or pDsRed1-GRβ (right panel) plasmids. Cell 
proteins were immunoprecipitated with mouse anti-Myc antibody and analyzed by IB with 
rabbit anti-Myc and GFP or RFP antibodies. d GRα and GRβ interact with the N-terminal of 
TCF-4. HEK293 cells were transfected with pDsRed1-GR727 and Myc-TCF-4, 
Myc-dnTCF-4 or pcDNA-Myc vectors. Cell proteins were immunoprecipitated with mouse 
anti-RFP antibody and analyzed by IB with rabbit anti-Myc and RFP antibodies. 
 
Fig. 5 GRβ knock-down, but not GRα reduced TCF/LEF transcriptional activity in GRβ 
knock-down stable U118 cells. a No changes of TCF/LEF transcriptional activity were 
witnessed in GRβ stable knock-down U118 cells after GR siRNA transfection. Cells were 
transfected with GR siRNA for 24h followed by a transfection with OT/OF and pRL-TK 
plasmids. b Western blot analysis of Cyclin D1 expression in GRβ stable knock-down U118 
cells transfected with GR siRNA for 72 h. β-actin served as a loading control. The lower 
panel shows the quantification of relative Cyclin D1 expression. c No significant effects of 
GR knock-down on cell growth in GRβ stable knock-down U118 cells were observed. d ChIP 
assay showed increased binding of TCF-4 to the Cyclin D1 promoter in GRβ stable 
knock-down U118 cells after a 72 h of pDsRed1-GRβ transfection. The right panel shows the 
quantification of relative DNA binding. **p< 0.01, n = 3. e Western blot analysis of Cyclin 
D1 expression in GRβ stable knock-down U118 cells transfected with pDsRed1-GRβ for 72 h. 
β-actin served as a loading control. The lower panel portrays the quantification result. *p< 
0.05, n = 3. 
 
Fig. 6 The effects of GRβ on Wnt signaling were dependent on the DBD and LBD. a 
Schematic view of full length hGRα, hGRβ and its deletion mutants used in b and c. 
C-terminal shaded domains in GRα and GRβ showed their specific portions. DBD 
DNA-binding domain, LBD Ligand binding domain, NTD N-terminal domain, AF2 
Activation functions 2 domain. b Interaction of TCF-4 and GRβ or its mutants were analyzed 
by IP and IB. COS-1 cells were transfected with Myc-TCF-4 and wtGRβ or its mutants. Cell 
proteins were immunoprecipitated with mouse Myc antibody and analyzed by IB with rabbit 
anti-RFP and Myc antibodies. c Luciferase assay of TCF/LEF transcriptional activity in 
COS-1 cells transfected with Myc-TCF-4 and wtGRβ or mutants for 48 h and followed by a 
transfection of OT/OF-Luc and pRL-TK vectors. Wnt1 (10 ng/ml) was added 6 h before assay. 
**p< 0.01, n = 3. 
 
Fig. 7 A working model of the function of GR on TCF/LEF transcriptional activity. In the 
absence of glucocorticoids (GCs), GRα localizes in the cytoplasm and GRβ is located in the 
nucleus. In the nucleus, GRβ enhances transcription of target genes by direct binding of the 
GRβ-specific response element (a) or by tethering itself to the TCF/LEF complex upon DNA 
binding (b). Upton binding GCs, cytoplasmic GRα undergoes an activation process and 
translocates to the nucleus, where it enhances or represses transcription of target genes by 
direct GRE binding (data not shown) or by interacting with other transcriptional factors and 
modulating their transcriptional activity. Ligand-activated GRα may compete with GRβ to 
form a heterodimer or homodimer which determines the inhibitory function of GRα on 
TCF/LEF transcriptional activity (c, d). 
 









